Evidence map›Paper›PMID 25859600›Full record

ReviewZhurnal evoliutsionnoi biokhimii i fiziologii

[Novel achievements in development and application of GPCR-peptides].

A O Shpakov, K V Derkach

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Zhurnal evoliutsionnoi biokhimii i fiziologii. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

A O Shpakov
K V Derkach
Institute of Evolutionary Physiology and Biochemistry · RURussian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the approaches to creating the regulators of G-protein-coupled receptors (GPCR) is the development of peptides that structurally correspond to the functionally important regions of the intracellular extracellular loops of the receptors. GPCR-peptides can selectively regulate the functional activity of homologous receptor and affect the hormonal signal transduction via the receptor. Among the peptides corresponding to the intracellular regions of GPCR, their derivatives modified with hydrophobic radicals exhibit the highest activity and selectivity of action in vitro and in vivo. Ample evidence demonstrates that lipophilic GPCR-peptides may be used to treat diseases and various abnormalities that depend on the functional activity of receptors homologous to them. In turn, the peptides corresponding to the extracellular regions of GPCR can be used as functional probes for studying the specific interaction between the receptors and their ligands, as well as for studying the etiology and pathogenesis of autoimmune diseases caused by the production of antibodies to GPCR antigenic determinants that are localized in the receptor extracellular loops. The present review focuses on the recent achievements in development and application of GPCR-peptides and on the prospects for their further use in medicine and fundamental biology.

Indexed as

AnimalsAutoimmune DiseasesHumansPeptidesProtein Structure, SecondaryProtein Structure, TertiaryReceptors, G-Protein-CoupledSignal TransductionPeptidesReceptors, G-Protein-Coupled

Identifiers

PMID25859600
OpenAlexW2125928460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.